UPI Journal of Pharmaceutical, Medical and Health Sciences
https://uniquepubinternational.com/journals/index.php/jpmhs
<div class="col-lg-9"> <div class="full-width"> <div id="pl-630" class="panel-layout"> <div id="pg-630-0" class="panel-grid panel-no-style"> <div id="pgc-630-0-1" class="panel-grid-cell"> <div id="panel-630-0-1-0" class="so-panel widget widget_sow-editor panel-first-child panel-last-child" data-index="2"> <div class="so-widget-sow-editor so-widget-sow-editor-base"> <div class="siteorigin-widget-tinymce textwidget"> <p data-start="103" data-end="404"><strong>UPI Journal of Pharmaceutical, Medical, and Health Sciences (UPI-JPMHS) ISSN: 2581-4532</strong> is a triannual (three issues per year), double-blind, peer-reviewed, open-access international journal. It welcomes submissions from all disciplines within the pharmaceutical, medical, and health sciences.</p> </div> </div> </div> </div> </div> </div> </div> </div>
en-US
<p><strong>Copyright © Author(s) retain the copyright of this article.</strong></p>
[email protected] (Chief Editor)
[email protected] (Gorre Venkata Nagaraju)
Fri, 30 Oct 2026 00:00:00 -0400
OJS 3.3.0.7
http://blogs.law.harvard.edu/tech/rss
60
-
Screen Time Exposure in Children Under Five Years in India: Magnitude, Consequences and the Case for a Nurse-Led Preventive Response: A Narrative Review
https://uniquepubinternational.com/journals/index.php/jpmhs/article/view/247
<p><strong>Background:</strong> The first five years of life are critical for neurodevelopment, with outcomes strongly influenced by responsive caregiver interactions. Screen exposure is increasingly common among Indian children, often beginning in infancy. <strong>Objective:</strong> To synthesise evidence on the prevalence, determinants and consequences of screen time among Indian children under five, examine caregiver knowledge and mediation practices, and identify nursing contributions to prevention. <strong>Methods:</strong> A narrative review was conducted using PubMed, Scopus and Google Scholar to identify literature published between 2015 and 2025 using terms related to screen exposure, early childhood, India and caregiver practices. World Health Organization and Indian Academy of Pediatrics guidelines were also consulted. Studies were selected based on relevance without formal systematic criteria or meta-analysis. <strong>Findings:</strong> Screen exposure among Indian children under five frequently exceeds recommended limits, with a reported pooled estimate of 2.22 hours daily. Guidelines recommend no screen exposure below 24 months and a maximum of one hour daily for children aged 24–59 months. Exposure is associated with parental education and occupation and is reinforced by screen use during feeding, emotional soothing and bedtime. Reported consequences include delayed expressive language, reduced attention, disturbed sleep, decreased physical activity and behavioural difficulties. However, evidence is predominantly cross-sectional. Caregiver awareness of age-specific recommendations appears limited, while randomised evidence suggests that structured parental education can reduce exposure. <strong>Conclusion:</strong> Excessive early screen exposure is a prevalent and modifiable concern in Indian child health. Nursing practice can address this gap through routine screening, age-appropriate anticipatory guidance and substitution-based counselling during immunisation, growth monitoring and Anganwadi visits. Integrating these strategies into existing services may strengthen caregiver awareness, promote healthier media habits and support early childhood development.</p>
Jayamala S. Goudar
Copyright (c) 2026
https://creativecommons.org/licenses/by-nc/4.0
https://uniquepubinternational.com/journals/index.php/jpmhs/article/view/247
Thu, 29 Oct 2026 00:00:00 -0400
-
Pharmacogenomics-Guided Precision Antimicrobial Therapy: From Genetic Variability to Personalized Treatment
https://uniquepubinternational.com/journals/index.php/jpmhs/article/view/248
<p>Pharmacogenomics (PGx) is a new branch of precision medicine that studies how genetic diversity influences differences in antimicrobial efficacy, drug exposure, toxicity, and treatment response. Although traditional antimicrobial therapy has significantly improved outcomes in infectious diseases, interindividual heterogeneity caused by pharmacokinetic, pharmacodynamic, clinical, pathogen-related, and genetic variables can all contribute to treatment failure or adverse drug reactions. This article outlines the pharmacogenomic foundation of antimicrobial response, which includes genetic diversity in drug-metabolizing enzymes, transporters, immune-related genes, and drug targets. Clinically relevant uses include HLA-B57:01 screening for abacavir hypersensitivity, MT-RNR1-associated aminoglycoside ototoxicity, CYP2B6-related efavirenz exposure, G6PD-associated toxicity, NAT2-related isoniazid metabolism, and CYP2C19-guided voriconazole therapy. The integration of pharmacogenomics with therapeutic drug monitoring, pharmacokinetic/pharmacodynamic modeling, model-informed precision dosing, fast diagnostics, artificial intelligence, and multi-omics may further assist personalized antimicrobial therapy. Pharmacogenomic testing tools ranging from targeted PCR and microarrays to next-generation and whole-genome sequencing open up new avenues for clinical use. India's wide genetic diversity and population-specific pharmacogenomic variations underscore the importance of representative genomic databases, standardized testing panels, clinical recommendations, and outcome-based validation. Despite significant advances, evidence for many antimicrobial gene-drug interactions is still sparse, and implementation is hampered by costs, infrastructure, interpretation, professional education, and unequal population representation. Future research should focus on varied populations, prospective clinical validation, integration with electronic health records, and evidence-based precision antimicrobial management.</p>
Rajulapati Devi Vara Prasad, Kurapati Pranathi, Parasa Akhil, P. Tabitha R. J. Chandrika
Copyright (c) 2026
https://creativecommons.org/licenses/by-nc/4.0
https://uniquepubinternational.com/journals/index.php/jpmhs/article/view/248
Mon, 09 Nov 2026 00:00:00 -0500